

Optimizing immunoPET imaging of tumor PD-L1 expression

AIM

Comparing PET imaging characteristics of three PD-L1 radioligands to monitor responses to anti-PD-1/anti-PD-L1 immunotherapies

METHODS

 Nude mice bearing subcutaneous human nonsmall cell lung cancer (NSCLC) xenografts;

• Labelling of 3 radioligands derived from the anti-PD-L1 IgG1 C4 using ⁸⁹Zr;

• Longitudinal PET/CT imaging (pharmacokinetics, biodistribution and dosimetry).

RESULTS

 C4 radioligands substantially accumulated in PD-L1 + tumor;

 Maximal tumor-to-muscle ratios obtained earlier, at 4 h post-injection (p.i.) for [⁸⁹Zr] Fab C4;

 Absorbed doses tolerable for repeated clinical PET imaging studies

CONCLUSION

 Design of radioligands with shorter PK for PD-L1 immunoPET imaging in a preclinical model

Promising for further clinical translation of such radioligands



Experimental protocol



microPET/CT imaging with the C4 radioligands in a PD-L1+ xenograft model - The three C4 radioligands were able to effectively detect PD-L1 expression in H1975 xenografts, but with different tumor uptakes and kinetics



PASREL-Imagerie: *in vivo* imaging to de-risk your medical innovations

A unique synergy of expertise & technologies to support your innovative projects



* 4 medical research imaging centers
* 34 technological platforms for preclinical and clinical research
* 10 research laboratories

pasrel-imagerie@pasrel-imagerie.com

PET, MRI, ultrasound, multimodal imaging and radiopharmaceutical production

• An access to a full range of scientific and technological solutions through one-stop shop and a dedicated project manager to support partner innovative developments from preclinical to clinical stages





www.pasrel-imagerie.com